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SUMMARY 44 
Metabolic reprograming is an emerging hallmark of tumor biology and an actively pursued 45 
opportunity in oncology drug discovery. Extensive efforts have focused on therapeutic 46 
targeting of glycolysis, whereas drugging mitochondrial oxidative phosphorylation 47 
(OXPHOS) has remained largely unexplored, partly due to an incomplete understanding of 48 
tumor contexts where OXPHOS is essential. Here, we report the discovery of IACS-010759, 49 
a clinical-grade small-molecule inhibitor of complex I of the mitochondrial electron 50 
transport chain. Treatment with IACS-010759 robustly inhibited proliferation and induced 51 
apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on 52 
OXPHOS, likely due to a combination of energy depletion and reduced aspartate 53 
production, leading to impaired nucleotide biosynthesis. IACS-010759 yielded potent 54 
tumor growth inhibition in vivo at well-tolerated doses in brain cancer and AML models 55 
and is currently being evaluated in Phase I clinical trials in relapsed/refractory AML and 56 
solid tumors. 57 
  58 
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Metabolic reprogramming is a well-appreciated hallmark of cancer, thus prompting extensive 59 
drug discovery activity in this area. Coordinated upregulation of glycolysis, known as the 60 
Warburg effect 1, is a phenomenon that arises as tumor cells adapt to increased demands for 61 
energy and biomass production. Elevated glycolysis is currently being exploited clinically using 62 
FDG-PET to detect metabolically active tumors 2, as well as therapeutically through the 63 
development of inhibitors of enzymes essential for glucose metabolism 3. Recent reports 64 
emphasize that, in addition to a strong dependence on glycolysis, many tumors or cancer cell 65 
subpopulations rely on OXPHOS 4 for bioenergetic 5-15 and biosynthetic processes 16,17. 66 
Biguanides, such as metformin, have been evaluated for the treatment of diabetes and metabolic 67 
disorders, providing rationale that targeting OXPHOS for clinical benefit can be done safely. 68 
However, metformin and other drugs targeting oxidative metabolism possess pharmacological 69 
limitations, including inadequate potency (i.e., biguanides) 18,19, transport-mediated accumulation 70 
(i.e., OCT1 for metformin) 20, off-target pharmacology (i.e., rotenone) 21, or lack of a suitable 71 
pharmacokinetic (PK) profile (i.e., oligomycin), which will restrict their use as oncology 72 
therapeutics. Here, we report the discovery of IACS-010759 (Fig. 1a), a clinical-grade, highly 73 
potent and selective small-molecule inhibitor of complex I of the mitochondrial electron 74 
transport chain (ETC; Fig. 1b) and its mechanism of anti-tumor activity in acute myeloid 75 
leukemia (AML) and genetically defined subsets of glioblastoma/neuroblastoma. 76 
IACS-010759 was identified through an extensive medicinal chemistry campaign of lead 77 
optimization initially seeded with known modulators of HIF1α that act via inhibition of 78 
OXPHOS 22-24. Consistent with IACS-010759 acting solely at complex I, treatment of detergent-79 
permeabilized cells with IACS-010759 in medium supplemented with pyruvate/malate (to 80 
generate NADH for use by complex I) resulted in attenuated oxygen consumption rate (OCR; 81 
4 
 
Fig. 1c), whereas OCR was not affected by treatment with IACS-010759 when medium was 82 
supplemented with succinate to feed complex II, thus bypassing the requirement for complex I 83 
function. The mechanism was further supported by the finding that ectopic expression of 84 
Saccharomyces cerevisiae NDI1, the yeast complex I ortholog 25,26, completely restored cell 85 
viability and OCR to baseline levels in the presence of IACS-010759 (Fig. 1d and 86 
Supplementary Fig. 1a,b). Similar results were obtained with rotenone, a well-established but 87 
less-specific complex I inhibitor (Supplementary Fig. 1c), although only a partial rescue of 88 
viability was observed, likely due to off-target toxicity (Supplementary Figs. 2b,d,g,i,j,l). 89 
Further, IACS-010759 treatment of complex I isolated from mouse mitochondria resulted in 90 
decreased catalysis due to inhibition at the ubiquinone-binding site versus the flavin site, with no 91 
effect on H2O2 generation (Fig. 1e). To define the interaction of IACS-010759 with complex I, 92 
clones with reduced sensitivity to IACS-010759 were generated by growing cells for 12 weeks in 93 
the presence of increasing amounts of IACS-010759 in galactose medium, wherein cells were 94 
rendered dependent on OXPHOS for survival 27,28. IC50 values for resistant clones ranged from 95 
3.7-74 nM, compared to 1.1 nM for parental cells (Supplementary Fig. 1d). In contrast, 96 
sensitivity to rotenone was minimally changed in most clones (Supplementary Fig. 1d), 97 
indicating that the reduced sensitivity was unlikely due to a general decrease in complex I 98 
dependence (see Fig. 1f for representative dose response curves for clone DC4 and parental cell 99 
line). Total and mitochondrial RNA from 12 clones was subjected to next-generation sequencing, 100 
which confirmed that nine of the clones contained an identical nucleotide change in their 101 
mitochondrial DNA (mtDNA; C3469T) yielding an L55F amino acid substitution in the ND1 102 
subunit of complex I (Fig. 1g). This residue resides close to the entrance of the proposed 103 
ubiquinone-10 binding channel of complex 1 (Figs. 1h,i) 29, but numerous attempts to ectopically 104 
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express mutant ND1-L55F utilizing multiple strategies were unsuccessful due to the technical 105 
challenges of ectopically expressing proteins encoded by mtDNA. Taken together, these data are 106 
consistent with IACS-010759 binding in or at the entrance to the ubiquinone channel, thus 107 
blocking ubiquinone binding or function to inhibit complex I activity. 108 
To correlate the phenotypic response directly with OXPHOS inhibition, the effect of IACS-109 
010759 on OCR of cells grown in Seahorse medium was compared to the viability of cells grown 110 
in galactose-containing medium. IACS-010759 robustly inhibited both OCR and galactose-111 
dependent cell viability, producing nearly identical IC50 values of 1.4 nM for both assays (Fig. 112 
1j). By comparison, rotenone treatment resulted in OCR and galactose-dependent cell viability 113 
IC50 values of 0.24 nM and 0.87 nM, respectively (Supplementary Fig. 1e). IC50 values were 114 
similar across several human cell line models for both compounds (Supplemental Table I). To 115 
inform on the potency of IACS-010759 across widely used preclinical safety species, the 116 
response of representative cell lines from mouse, rat, dog, and cynomolgus monkey were 117 
assessed using the highly quantitative galactose growth assay. IACS-010759 was similarly active 118 
in mouse (Avg. IC50 = 5.6 nM), rat (IC50 = 12.2 nM) and cynomolgus monkey (IC50= 8.7 nM), 119 
thus making them appropriate preclinical models for further safety studies (Supplemental Table 120 
I). In contrast, IACS-010759 was minimally active in canine cell lines (IC50 180 nM to 360 nM). 121 
Rotenone potency was very similar across all species (Supplemental Table I).   122 
The effect of IACS-010759 on cell growth and viability was evaluated across a panel of cancer 123 
cell lines and normal diploid cells standard culture medium containing IACS-010759, which 124 
provides multiple energy sources to the cells. IACS-010759 yielded a >50% maximal reduction 125 
in growth in the majority of cancer cell lines (24/30 pancreatic (PDAC), 19/20 ovarian, 13/16 126 
triple-negative breast (TNBC), 8/10 non-small cell lung (NSCLC)), while a subset (11/30 PDAC, 127 
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10/20 ovarian, 5/16 TNBC and 2/10 NSCLC) exhibited >100% growth inhibition 128 
(Supplementary Fig. 3a-d). All diploid cell lines were insensitive to IACS-010759 with little or 129 
no growth inhibition (Supplementary Fig. 2a,c,g,i,k), whereas rotenone exposure reduced 130 
viability in these models, consistent with rotenone possessing non-specific “off-target” toxicities 131 
(Supplementary Fig. 2b,d,h,j,l). These data establish differential sensitivity of normal and cancer 132 
cells to OXPHOS inhibition by IACS-010759. 133 
In addition to direct anti-growth effects, OXPHOS inhibition has been reported to reduce 134 
hypoxia and HIF pathway activity 4,22,24,30. Consistently, exposure of cell line spheres to IACS-135 
010759 eliminated hypoxia, most likely as a consequence of increased intracellular oxygen 136 
(Supplementary Fig. 4a,b). This coincided with decreased HIF pathway activity (Supplementary 137 
Fig. 4c) via oxygen-, prolyl hydroxylase- and VHL-dependent degradation of HIF1α 138 
(Supplementary Figs. 4d-h).  139 
IACS-010759 targets glycolysis-deficient tumor cells 140 
Glycolysis is under negative control by OXPHOS and is induced by tricarboxylic acid cycle 141 
(TCA)-mediated allosteric inhibition of glyocolytic enzymes (the “Pasteur effect” 31); therefore, 142 
genetic or pharmacological OXPHOS inhibition should result in compensatory upregulation of 143 
glycolysis to maintain ATP levels and redox balance, resulting in modest anti-proliferation 144 
effects 32. We thus hypothesized that tumor cells with reduced capacity for compensatory 145 
glycolysis would be more sensitive to OXPHOS inhibition.  146 
As previously reported, a subpopulation of brain tumor cell lines with homozygous deletion of 147 
Enolase 1 (ENO1) are glycolysis deficient due to a >90% reduction of cellular enolase enzymatic 148 
activity 33,34. Consistent with glycolysis inhibition at enolase, the levels of glycolysis metabolites 149 
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upstream of enolase were elevated in ENO1-null cell lines, such as D423 and Gli56, while 150 
metabolites downstream of enolase were reduced relative to glioblastoma multiforme (GBM) 151 
cell lines heterozygous or wild-type for ENO1 (Supplementary Fig. 5a). Ectopic expression of 152 
wild-type ENO1 in Gli56 and D423 (Supplementary Fig. 5b) robustly increased lactate 153 
production, consistent with restoration of glycolysis (Fig. 2a and Supplementary Fig. 5c). 154 
Further, there was minimal lactate production upon treatment of parental Gli56 cells with IACS-155 
010759, whereas the baseline and induction of lactate production were substantially increased in 156 
Gli56 cells ectopically expressing ENO1 (Supplementary Fig. 5d). Similar to ENO1-null cells, 157 
phosphoglycerate dehydrogenase (PGD)-null cells, such as the NB1 cell line, are glycolysis 158 
deficient, as these cells accumulate 6-phosphogluconate, an allosteric inhibitor of glucose-6-159 
phosphate isomerase 35,36,37. We evaluated the metabolic profile of NB1 cells by determining the 160 
ECAR:OCR ratio (Fig. 2b), and observed both an extremely low glycolysis:OXPHOS ratio and 161 
restored lactate production following ectopic expression of PGD (Fig. 2a). Furthermore, IACS-162 
010759 treatment resulted in  >70% reduction in viability and a 2- to 5-fold increase in apoptosis 163 
in NB-1, GLI56, or D423 cells, while ectopic expression of either ENO1 or PGD (Fig. 2c,d and 164 
Supplementary Figs. 6a-c) substantially attenuated the response. Similarly, the viability of 165 
ENO1-/- or ENO1+/- glioma sphere-derived cell lines was reduced upon IACS-010759 exposure 166 
(Supplementary Fig. 6d-f). These data are consistent with our hypothesis that glycolysis 167 
deficiency renders cell lines highly sensitive to OXPHOS inhibitors such as IACS-010759. 168 
AML tumor cells are sensitive to IACS-010759 169 
Previous reports have suggested that leukemia cells are highly OXPHOS dependent 6,7,11-13,38-40, 170 
warranting evaluation of IACS-010759 in AML models. Established AML cell lines were 171 
exposed to a range of IACS-010759 concentrations for 3 to 7 days, resulting in reduced viability 172 
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with EC50 values of <3 nM (Fig. 2e and Supplementary Fig. 7a). While the inflection point of 173 
response (EC50) was equivalent across cell lines (Supplementary Fig. 7a), the effect on viability 174 
varied, with MOLM-13 (FLT3-ITD mutated) being relatively insensitive (Fig. 2e). Treatment 175 
with IACS-010759 uniformly reduced OCR, indicating that the differential effects on viability 176 
are not due to lack of OXPHOS inhibition, consistent with our finding of similar EC50 values 177 
across cell lines (Supplementary Fig. 7b). In most cell lines, IACS-010759 treatment modestly 178 
increased apoptosis by up to 2-fold (Fig. 2h). Cells responded more robustly to IACS-010759 179 
treatment when glucose availability was restricted, whereas glutamine restriction did not enhance 180 
the response (Supplementary Fig. 7c,d), consistent with glucose utilization being the primary 181 
compensatory response to OXPHOS inhibition. Interestingly, MOLM-13 had the highest 182 
baseline OCR and largest glycolytic reserve of the cell lines evaluated, both of which may 183 
contribute to its relative insensitivity to IACS-010759 (Supplementary Fig. 7b). This might 184 
represent a potential mechanism for treatment resistance and is consistent with results reported 185 
for OXPHOS inhibition in melanoma models 41. We extended our studies to primary AML blasts 186 
isolated from peripheral blood of relapsed/refractory patients by treating blasts ex vivo with 187 
multiple concentrations of IACS-010759 for up to 5 days. In nearly all primary AML samples, 188 
but not in non-transformed mononuclear cells isolated from normal bone marrow, IACS-010759 189 
reduced viability and induced apoptosis (Fig. 2f,g,i,j and Supplemental Table II), consistent with 190 
our observations in AML cell lines and supporting a therapeutic window for IACS-010759 to 191 
selectively target leukemic versus normal hematopoietic cells. The patient-derived xenograft 192 
(PDX-4030094), also responded robustly to IACS-010759 (approximate IC50 <1.5 nM) upon ex 193 
vivo treatment (Supplementary Fig. 7e). Further, we evaluated IACS-010759 response in cell 194 
lines established from two previously described murine AML models genetically engineered to 195 
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ectopically co-express the clinically relevant translocation MLL/ENL in a KRASG12D background 196 
with or without TP53 deletion 42. Viability and OCR were inhibited equally in both cell lines 197 
(Supplementary Fig. 7f,g) with approximate IC50 values of 20 nM and 55 nM, respectively. 198 
These results, taken together with those in ENO1- and PGD-null GBM models, define two 199 
biological tumor contexts with striking sensitivity to IACS-010759.   200 
IACS-010759 safely targets glycolysis-deficient tumors in vivo 201 
To determine whether the observed in vitro and ex vivo effects predicted in vivo responses in 202 
preclinical models at tolerated doses, we evaluated IACS-010759 in murine models of 203 
glioblastoma/neuroblastoma and AML. The PK profile of IACS-010759 was determined in mice 204 
following intravenous (0.3 mg/kg) and oral (1 mg/kg) administration (Supplementary Fig. 8a). 205 
IACS-010759 was characterized by low plasma clearance with a high volume of distribution, 206 
resulting in a prolonged terminal half-life (>24 hours) with sustained levels of plasma exposure 207 
following oral dosing. Conversion of IACS-010759 free base into the corresponding HCl salt 208 
resulted in a ~10-fold increase in plasmatic exposure after oral dosing (Supplementary Fig. 8b). 209 
Consistent with previous reports for metformin43, we did not observe changes in blood glucose 210 
level with single or repeated doses of IACS-010759 (Supplementary Fig. 8c). However, at 2 211 
hours post a first or fifth dose, plasma insulin levels transiently decreased, returning to control 212 
levels by 24 hours post-dose (Supplementary Fig. 8d).   213 
To assess the tolerability and anti-tumor activity of IACS-010759 in a glycolysis-deficient 214 
context, mice bearing NB-1 (PGD-null) subcutaneous xenografts received daily oral doses of 0, 215 
5, 10, or 25 mg/kg/day free base IACS-010759 for 21 days. Treatment with 5 or 10 mg/kg IACS-216 
010759 resulted in tumor regression with minimal body weight loss (Fig. 3a and Supplementary 217 
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Fig. 8e), whereas IACS-010759 25 mg/kg was not tolerated, with observations of body weight 218 
loss (Supplementary Fig. 8e), lethargy, and hypothermia. At the tolerated doses, IACS-010759 219 
was equally effective and well tolerated with various intermittent dosing schedules 220 
(Supplementary Fig. 8f,g), providing flexibility for dosing. Transient, intermittent treatment of 221 
Gli56 intracranial tumors with 5 mg/kg IACS-010759.HCl using a 5 day on/2 day off schedule 222 
for 4 weeks reduced tumor size as measured by MRI (Figs. 3b,c) and extended median survival 223 
from 84 days to 130 days (Supplementary Fig. 9a). Tumor hypoxia was eliminated in Gli56 and 224 
D423 intracranial tumors after two daily doses of IACS-010759.HCl 5 mg/kg (Supplementary 225 
Fig. 9b,c) compared to vehicle control-treated animals, supporting OXPHOS inhibition within 226 
the tumor. We also observed 84% and 43% reductions in the number of cells positive for the 227 
mitotic marker phospho-histone H3 in IACS-010759.HCl-treated Gli56 and D423 tumors, 228 
respectively, compared to control-treated animals (Supplementary Fig. 9d-g), which is indicative 229 
of reduced tumor cell proliferation. Collectively these data provide evidence of profound anti-230 
tumor activity of IACS-010759 at well-tolerated doses in the context of glycolysis-deficient 231 
brain tumors. 232 
Immunohistochemistry (IHC) analysis of tumor samples from 92 patients treated at The 233 
University of Texas MD Anderson Cancer Center was conducted to determine the prevalence of 234 
ENO1- and PGD-null GBM toward defining a potential clinical path. Eight tumors (8.6%) were 235 
either unambiguously ENO1-negative (3.3%) or showed very low ENO1 staining (5 tumors 236 
(5.3%)), which represented a slightly higher percentage of ENO1-deficient tumors compared to 237 
reports from The Cancer Genome Atlas (TCGA) sequencing data (Fig. 3d and Supplementary 238 
Fig. 9h). Whether tumors with weak staining represent non-specific background or very low 239 
expression of ENO1 could not be ascertained and will require independent validation with 240 
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orthogonal assays. Regardless, a clinically relevant population of at least 3% was clearly 241 
identified. It should be noted that the strong, residual signal represents ENO1 expression in non-242 
tumor stromal cells, such as microglia, lymphoid cells, and blood vessel endothelial and smooth 243 
muscle cells (Supplementary Fig. 9i,j and 10a-d). No tumors PGD-null tumors were identified. 244 
Based on this analysis, we conclude that ENO1-depleted GBM tumors can be detected and 245 
therefore represent a viable, clinically relevant population expected to benefit from treatment 246 
with IACS-010759.  247 
IACS-010759 is tolerated and extends survival in murine models of AML 248 
In vivo AML models were evaluated to confirm the anti-tumor activity and tolerability of IACS-249 
010759 in this context. The OCI-AML3 cell line, PDX-4030094 (MLL-rearranged AML PDX 250 
model refractory to standard-of-care treatment), PDX-S6-AP (PDX with complex cytogenetics 251 
and unfavorable prognosis), and three genetically defined murine leukemia syngeneic models42 252 
were grown orthotopically in mice. Seven days after inoculation with OCI-AML3 cells, mice 253 
were dosed orally for 35 days with 10 mg/kg IACS-010759.HCl or vehicle using several 254 
intermittent schedules (Fig. 3e) and doses that were all well tolerated (Supplementary Fig. 11a, 255 
11c). Daily dosing schedules (QD or 5 on/2 off) were most effective and increased median 256 
survival from 28 days to longer than 60 days, while less-frequent dosing schedules (Q2D or 257 
Q3D) enhanced survival to a lesser extent (Fig. 3e). In the PDX-4030094 model, IACS-258 
010759.HCl 2.5 or 7.5 mg/kg/day nearly doubled median survival from 35 days to almost 70 259 
days (Fig. 3f and Supplementary Fig. 11b), while IACS-010759.HCl 1 mg/kg/day extended 260 
survival to 55 days. Additionally, disease burden, as measured by splenic hCD45 abundance at 261 
treatment day 21, was significantly reduced in IACS-010759-treated groups relative to vehicle-262 
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treated groups (Supplementary Fig. 11d). IACS-10759 similarly improved survival in the PDX-263 
S6-AP model (Supplementary Fig. 11e). Treatment of the highly aggressive, matched-pair 264 
MLL/ENL translocation syngeneic models with IACS-010759 resulted in modest but statistically 265 
significantly prolonged survival in the TP53-/-, but not the TP53+/+ model (Supplementary Fig. 266 
11f,g). In contrast, the murine syngeneic model, AML1/ETO9a (KRASG12D, p53-null), was more 267 
sensitive to IACS-010759, with significant decreases in disease burden at days 8 (42%) and 15 268 
(24%) (Supplementary Fig. 11h) and statistically significantly extended median survival from 17 269 
days to 21 days (24%) (Supplementary Fig. 11i). Similarly to the xenograft models, all three 270 
syngeneic models experienced transient loss of body weight during the first week of dosing 271 
(Supplementary Fig. 11j-l). Overall, the consistent anti-leukemia responses observed in vitro and 272 
in vivo provided the preclinical rationale to evaluate IACS-010759 in a phase 1 study in subjects 273 
with relapsed/refractory AML (NCT02882321), which enrolled its first subject in October 2016.  274 
OXPHOS inhibition leads to depletion of energy and nucleotide biosynthesis 275 
To better understand the molecular mechanism by which IACS-010759 exerts anti-tumor 276 
activity, we performed metabolomic analyses, stable-isotope tracing experiments, and functional 277 
characterization on a subset of AML cell lines. IACS-l010759 induced modest increases in ROS 278 
levels, consistent with previous reports examining OXPHOS inhibition41,44 (Supplementary Fig. 279 
12a). To evaluate metabolic reprogramming, OCI-AML3 cells were exposed to IACS-010759 280 
for 6, 24, or 72 hours, and the resultant cell lysates were subjected to LC/MS analysis to measure 281 
metabolites from central carbon metabolism and amino acids. IACS-010759 treatment elevated 282 
the intracellular steady-state level of the complex I substrate, NADH, as well as nucleotide 283 
monophophates (NMPs), while reducing nucleotide triphophates (NTPs), all consistent with 284 
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complex I inhibition and reduced energetic status (Fig. 4a). This was further confirmed by 285 
elevated pT172-AMPK levels (see Fig. 4j, Supplementary Fig. 12m), a well-established readout of 286 
energetic stress. Stable isotope-tracing experiments using uniformly labelled 13C-glucose (Fig. 287 
4b) revealed that IACS-010759 significantly increased incorporation of 13C-glucose into the 288 
glycolysis endpoints lactate and alanine, as evaluated by m+3 isotopologue fractions (Fig. 4c), 289 
and decreased incorporation into TCA intermediates and mitochondria-produced metabolites 290 
(m+2 isotopologue fractions), including aspartate and glutamate (Fig. 4d), suggesting that 291 
glucose utilization through these pathways was significantly reduced. Although IACS-010759-292 
treated cells uptake less glutamine compared to control cells (Supplementary Fig. 12b), tracing 293 
experiments with uniformly labeled 13C-glutamine confirmed that treatment with IACS-010759 294 
increased incorporation of 13C-glutamine carbons into the TCA cycle to fuel both oxidative and 295 
reductive metabolism, likely to support fatty acid biosynthesis, but failed to productively 296 
contribute toward aspartate synthesis (Supplementary Fig. 12c-f) 45. These observations suggest 297 
an increased utilization of glutamine as an alternative compensatory mechanism to IACS-010759 298 
treatment. 299 
Targeted metabolomics in OCI-AML3 cells showed that, consistent with other published 300 
findings 16,17. To assess whether aspartate was incorporated into nucleotides, as has been 301 
suggested 16,17, OCI-AML3 cells were grown with uniformly labelled 13C-aspartate. After 302 
treatment with IACS-010759, an increased m+3 isotopologue fraction of several nucleotides was 303 
observed (Fig. 4f,g) that was consistent with increased utilization of exogenous aspartate for 304 
nucleotide biosynthesis, which suggests that mitochondria-produced aspartate becomes rate 305 
limiting upon OXPHOS inhibition. While aspartate supplementation partially restored cell 306 
growth (Fig. 4h, Supplementary Fig. 12g,h), cell cycle progression, and incorporation of BrdU 307 
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into cycling cells (Fig. 4i, Supplementary Fig. 12i), it failed to influence pT172-AMPK activation, 308 
indicating persistent energetic stress (Fig. 4j, Supplementary Fig. 12m). Interestingly, AMPK 309 
activation does not appear to be essential for the reduced tumor cell viability observed upon 310 
IACS-010759 exposure, as shRNA-mediated knockdown of AMPK in OCI-AML3 cells 311 
minimally impacted cell viability (Supplementary Fig. 12j,k). Aspartate also abrogated IACS-312 
010759-induced accumulation of DNA damage, as measured by pS139-γH2AX (Fig. 4j). 313 
Interestingly, aspartate supplementation was not able to rescue the proliferation phenotype in the 314 
relatively insensitive MOLM-13 cell line, suggesting that the hypersensitive cell lines may rely 315 
on OXPHOS for energy as well as aspartate production (Supplementary Fig. 12h). As an 316 
additional response mechanism, we found that IACS-010759 markedly increased expression of 317 
the CD14 myeloid differentiation marker in OCI-AML3 cells (Supplementary Fig. 12l), but not 318 
in MOLM-13 cells (data not shown). Taken together, we propose that IACS-010759-mediated 319 
reduction in cell viability and induction of differentiation or apoptosis result from a combination 320 
of energy depletion and reduced aspartate production (Fig. 5a,b). 321 
Therapeutic targeting of OXPHOS in AML 322 
Based on mechanisms defined by in vitro studies, we evaluated the effects of IACS-010759 on 323 
OCR, aspartate, proliferation, and differentiation status in blast cells from PDX-4030094 in vivo. 324 
Blast cells were harvested from mouse spleens 2 hours after the first dose or 24 hours after a 325 
second dose of IACS-010759.HCl (representing Cmax and Ctrough, respectively; Fig. 5b). At each 326 
dose and time point, OCR, aspartate, and an IACS-010759-regulated transcriptomic signature 327 
(Supplementary Fig. 13a-f) were measured to establish a relationship among PK, 328 
pharmacodynamic (PD), and efficacy outcomes. At 2 hours, OCR was equally inhibited at all 329 
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doses (Fig. 5c, Supplementary Fig. 14a). By 48 hours, OCR (Fig. 5d, Supplementary Fig. 14b), 330 
aspartate (Fig. 5f) and the gene expression signature (Fig. 5g) were suppressed in a dose-331 
dependent manner at the 2.5- and 7.5-mg doses, which correlated with increased survival (see 332 
Fig. 3f). At both time points, aspartate levels were unaltered at 1 mg/kg but suppressed in a dose-333 
dependent manner at the top two doses (Fig. 5e,f), suggesting that aspartate level is a less-334 
sensitive measure than OCR or the gene expression signature. Blasts isolated from animals that 335 
received two doses of IACS-010759 (7.5 mg/kg) exhibited reduced proliferation (Fig. 5h) and 336 
increased apoptosis (Fig. 5i). Additionally, IACS-010759 treatment reduced the fraction of 337 
CD34+ stem/progenitor AML cells (Fig. 5j) in a dose-dependent manner, most likely due to 338 
induction of leukemia cell differentiation, as suggested by enrichment of AML cells expressing 339 
the myeloid differentiation antigens, MNDA, CD14, CD11b, and CD68 (Fig. 5k and 340 
Supplementary Fig. 15a-k). These data support employing OCR, aspartate levels, gene 341 
expression changes, and markers of differentiation as PD biomarkers to assess the biology of 342 
response in clinical samples from patients with relapsed/refractory AML treated with OXPHOS 343 
inhibitors such as IACS-010759. 344 
Advancing IACS-010759 into clinical evaluation  345 
The anti-tumor activity of IACS-010759 in glycolysis-deficient GBM/neuroblastoma tumors and 346 
relapsed/refractory AML justified evaluation of IACS-010759 in clinical studies. During 347 
preclinical development, we evaluated IACS-010759 PK in mouse, rat, dog, and cynomolgus 348 
monkey, which indicated that the compound displayed low clearance, large volume of 349 
distribution, and long terminal half-life (Supplementary Table III). In a battery of in vitro studies, 350 
IACS-010759 did not show any significant effects in binding assays on a panel of 80 receptors 351 
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and ion channels (Supplemental Table IV), nor did IACS-010759 inhibit the hERG K+ channel 352 
current (IC50 >30 µM) (Supplementary Fig. 16) or modulate CYP enzyme activity (data not 353 
shown). In in vivo toxicity studies that included dose-range finding, acute intravenous dosing, 354 
repeated oral dosing (both daily and intermittent), and a pivotal GLP-compliant 28-day oral 355 
toxicity study with a 28-day recovery period in the Sprague-Dawley rat and cynomolgus 356 
monkey, drug-related adverse events included emesis and decreased body weight at lower doses. 357 
At the highest doses, decreased core body temperature and death were observed, consistent with 358 
anticipated effects of excessive OXPHOS inhibition. No-observed-adverse-effect dose levels 359 
(NOAELs) were identified in rat and monkey that supported the ability for oral daily doses to 360 
yield plasma drug concentrations above those anticipated to result in on-target drug effects. 361 
These data were used to establish the human starting dose per FDA guidelines 46.  362 
Our findings contrast with the century-old tenet, put forth in Otto Warburg’s seminal work, that 363 
glycolysis is the dominant metabolic pathway to which tumors become addicted1. In recent 364 
years, the field has dispelled the notion that the increased glycolysis observed in tumors is simply 365 
a mechanism to provide additional energy to support the high rate of proliferation, and instead 366 
has indicated that the adaptation serves to provide macromolecule building blocks for 367 
biosynthetic processes that are critical for enhanced tumor growth. Through the development and 368 
characterization IACS-010759, we now provide evidence that clinically translatable contexts 369 
exist where tumors are highly dependent on OXPHOS for survival. We further demonstrate that 370 
subsets of tumors depend on OXPHOS not only for ATP synthesis, but also to produce 371 
macromolecules necessary for biosynthetic processes, similar to glycolysis. In the most sensitive 372 
tumor cells, OXPHOS disruption creates an environment of energy and macromolecule depletion 373 
that leads to cell cycle arrest, apoptosis, and, in the case of AML, differentiation, similar to what 374 
17 
 
has been reported with small-molecule inhibitors of mutant IDH 47. Taken together, our 375 
preclinical data support clinical evaluation of IACS-010759 in AML and solid tumors that lack 376 
compensatory glycolytic capacity. First-in-human clinical studies with IACS-010759 are 377 
ongoing in patients with AML and solid tumors to establish proof-of-concept, define the 378 
maximum tolerated dose, and provide initial verification of the hypotheses generated by this 379 
work.  380 
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FIGURE LEGENDS 608 
Figure 1. IACS-010759 is a potent inhibitor of mitochondria complex I. (a) Structure of 609 
IACS-010759. (b) Illustration of mitochondria electron transport chain. (c) OCR in 610 
permeabilized H460 cells grown in medium supplemented with pyruvate/malate to measure 611 
complex I activity, then treated with IACS-010759 (Injection I) and 10 mM succinate (Injection 612 
II) (n=2 cultures performed one time). (d) OCR in Seahorse medium (n=6 cultures, 613 
representative experiment out of 2 experiments) and relative viability (cell confluence) in 614 
galactose medium (n=2 cultures performed one time) were measured in H460 cells engineered to 615 
ectopically express Saccharomyces cerevisiae Ndi1 (complex I equivalent) or GFP following 616 
treatment with either DMSO or 14 nM IACS-010759 for 1 hour (OCR) or 72 hours (viability). 617 
(e) Complex I isolated from mouse mitochondria was treated with 60 nM IACS-010759 to 618 
measure effects on ubiquinone reduction (decylubiquinone) (n=9 technical replicates), flavin site 619 
activity via APAD+ (n=3 technical replicates), and H2O2 production (n=3 technical replicates). (f) 620 
Dose-response for H292 clone resistant to IACS-010759 (n=2 cultures, performed one time). (g) 621 
Sanger sequencing chromatogram of PCR-amplified MT-ND1 DNA from an IACS-010759-622 
resistant cell. (h) Structure of complex I showing location of ND1 subunit. (i) Location of L55F 623 
relative to the proposed ubiquinone binding channel (shown as a surface) in complex I. Residues 624 
and structures that form the binding site are shown; the redox-active ubiquinone headgroup 625 
moves through the channel and is reduced next to cluster N2. (h) and (i) were created using the 626 
highly homologous structure of bovine complex I (5LC5.pdb) 29.  (j) H460 cells were treated 627 
with IACS-010759 and OCR (n=6 cultures) and viability (n=2 cultures) were measured after 1 or 628 
72 hours, respectively.  ***p-value <0.0001 by two-sided student’s t-test. c,d,j repeated once; e,f 629 
repeated ≥ 2 times, each with comparable results. 630 
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 631 
Figure 2. Glycolysis deficient and AML tumor cells are sensitive to OXPHOS inhibition. 632 
(a) Extracellular lactate levels (glycolysis endpoint) in NB1 (6PGD-/-), Gli56 (ENO1-/-) and D423 633 
(ENO1-/-) cells and their counterparts each engineered to ectopically express either PGD (NB1) 634 
or ENO1 (Gli56 and D423) (Data represents the mean value of n=6 cultures for NB1 and D423 635 
and n=3 cultures for Gli56). (b) Seahorse analysis measuring the ratio of glycolysis (proton 636 
production rate, PPR) to OXPHOS (OCR), (n=2 biological replicates). (c) Viability of same 637 
matched pair cell lines cultured in medium containing 100 nM IACS-010759 for 3 days (n=2 638 
biological replicates for NB1 and D423; n=3 biological replicates for Gli56). (d) Percentage of 639 
annexin V-positive (+) NB1, Gli56, and D423 cells cultured in medium containing DMSO or 640 
100 nM IACS-010759 for 3 days (n=3 cultures). (e) Viability of AML cell lines treated with 641 
indicated concentrations of IACS-010759 for 3 to 7 days (Data represents mean ± SD from n=3 642 
cultures). (f) Viability of primary AML or (g) normal bone marrow samples treated ex vivo with  643 
0, 10, 30 or 100 nM IACS-010759 for 4 or 5 days. IACS-010759-treated samples were 644 
normalized to corresponding DMSO-treated control. (h) Percentage of apoptotic cells 645 
(PI/annexin V) for each AML cell line (n=2 cultures, with replicate study performed only for 646 
OCI-AML3 with comparable results) after culturing for 72 hours in medium containing DMSO 647 
or 123 nM IACS-010759. (i) Percentage of apoptotic (annexin V positive) cells for primary 648 
AML or (j) normal bone marrow cells after culturing for 4 or 5 days in medium containing 649 
DMSO or IACS-010759. For f,g,i, and j, each point is the mean of 3 cultures from a single 650 
patient sample performed once; the bar for each concentration represents the mean value for all 651 
of the samples; patient sample (UPIN) characteristics are included in Supplementary Table II.  p-652 
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value ***<0.0001, **<0.001,*<0.05 by two-sided student’s t-test. a-e, repeated one additional 653 
time with comparable results.  654 
 655 
Figure 3. Glycolysis-deficient and AML xenografts are sensitive to OXPHOS inhibition. (a) 656 
Tumor volume of subcutaneous NB1 tumors in mice that received daily oral dosing of IACS-657 
010759 or vehicle. (n=10 per group; data represents mean ± SEM). (b,c) Mice with ENO1-658 
deficient Gli56 cells implanted intracranially were treated with vehicle or 5 mg/kg IACS-010759 659 
for 4 weeks following a 5 on/2 off dosing schedule: (b) Representative pre- and post-treatment 660 
MRI coronal images of brain (vehicle n=5 mice, IACS-010759 n=7 mice; experiment repeated 661 
once with similar results). (c) Quantitation of tumor volumes calculated from MRI images at Day 662 
33; (Box-whisker plots, min to max *p = 0.025 using two-sided Student’s t-test). (d) 663 
Hematoxylin & eosin (H & E) and immunohistochemistry staining for 6PGD and ENO1 protein 664 
expression in GBM patient tumor array. Representative ENO1 wild-type (WT) and ENO1-null (-665 
/-) tumors are shown. Scale bar = 100 µm. (e) Kaplan-Meier survival analysis of mice inoculated 666 
with OCI-AML3 cells and treated for 5 weeks (starting on Day 7) with oral vehicle or 10 mg/kg 667 
IACS-010759 daily (QD), 5 days on/ 2 days off (QDx5), every other day (Q2D), or every third 668 
day (Q3D). (n = 9 mice per group, p-values = 0.0007 [Q3D], 0.0008 [Q2D] and <0.0001 [QD 669 
and QDx5] by Mantel-Cox Log-rank test using GraphPad prism software) (f) Kaplan-Meier 670 
survival analysis of mice inoculated with primary patient sample 4030094 and treated with oral 671 
1, 2.5, or 7.5 mg/kg IACS-010759 daily starting on Day 25.  (n = 9 mice per group, p-values = 672 
0.0002 [1 mg/kg] and <0.0001 [2.5 and 7.5 mg/kg] by Mantel-Cox Log-rank test using 673 
GraphPad prism software) 674 
 675 
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Figure 4. Inhibition of OXPHOS by IACS-010759 leads to energy deprivation and impairs 676 
nucleotide biosynthesis. (a) Targeted metabolomic analysis of nucleotide biomolecules in OCI-677 
AML3 cells treated with 100 nM IACS-010759 for 6, 24, or 72 hr. The heatmap depicts 678 
alterations of metabolites associated with complex I and energy production as fold-change (log2) 679 
of treated versus DMSO control. p-values were derived using two-sided Welch’s t-test 680 
accounting for unequal variance (n=4 cultures, mean, experiment repeated once with comparable 681 
results). (b) Illustration of [U-13C]-glucose metabolism in OCI-AML3 cells. White circles = 12C 682 
carbons; blue circles = 13C carbons. Cells were grown in culture medium containing [U-13C]-683 
glucose and treated with DMSO or 100 nM IACS-010759 for 24 hours. (c) Incorporation of [U-684 
13C]-glucose into glycolysis endpoints [lactate (extracellular) and alanine (intracellular)], (n=4 685 
cultures, mean plotted, p-value ***=0.0002, ****<0.0001 by two-sided Student’s t-test.). (d) 686 
TCA intermediates (isocitrate, α-ketoglutarate, succinate and fumarate [intracellular]) and 687 
mitochondria metabolites (glutamate, glutathione and aspartate [intracellular]) in OCI-AML3 688 
cells after treatment with DMSO or 100 nM IACS-010759 for 24 hours. (n=4 cultures, mean 689 
plotted, p-value ****<0.0001 by two-sided Student’s t-test). (e) Targeted metabolomic analysis 690 
of amino acid biomolecules in OCI-AML3 cells treated with DMSO or 100 nM IACS-010759 691 
for 6, 24, or 72 hours. The heatmap depicts alterations of as fold-change (log2) of treated versus 692 
DMSO control samples. p-values were derived using two-sided Welch’s t-test accounting for 693 
unequal variance (; n=4 cultures, mean, experiment repeated once with comparable results). (f) 694 
Illustration of conversion of [U-13C]-aspartate carbon into pyrimidines. Blue circles depict 695 
carbons derived from aspartate. (g) Incorporation of carbons derived from [U-13C]-aspartate into 696 
representative pyrimidine metabolites in OCI-AML3 cells treated with DMSO or 100 nM IACS-697 
010759 for 72 hours. (n=4 cultures, mean plotted, experiment repeated once with comparable 698 
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results). (h) OCI-AML3 cells were cultured in medium treated with DMSO, 100 nM IACS-699 
010759, or 100 nM IACS-010759 supplemented with 10 mM aspartate and the number of cells 700 
was measured after 72 hours (n=2 cultures, experiment repeated once with comparable results). 701 
(i) Incorporation of BrdU measured by flow cytometry in OCI-AML3 cells treated for 72 hours 702 
with DMSO, 123 nM IACS-010759, or 123 nM IACS-010759 supplemented with 10 mM 703 
aspartate. Cells were also stained with 7-AAD to detect DNA. (j) Immunoblot for activated 704 
AMPK (p-AMPK, T172) and γ-H2AX (p-γ-H2AX, S139) in OCI-AML3 cells treated as 705 
described.  See supplementary figure 12m for blots with molecular weight markers.  i,j repeated 706 
once with comparable results. 707 
Figure 5. IACS-010759 modulates several clinically translatable pharmacodynamic 708 
biomarkers (a) Experimental workflow to assess pharmacokinetic and pharmacodynamic 709 
relationship for mice inoculated with PDX-4030094 cells and treated with IACS-010759.  (b) 710 
Illustration schema for workflow to assess PD markers of target inhibition and biology of 711 
response. After irradiation and inoculation, tumor burden was monitored. Upon 90% tumor 712 
burden in the spleen (human CD45 versus mouse CD45), mice received 2 doses of IACS-010759 713 
24 hours apart. Tumor cells were isolated from the spleen at 2 hours after the first dose or 24 714 
hours after the second dose (2-hour (Cmax) and 48-hour (Cmin) time points, respectively). (c) OCR 715 
of leukemia cells at the 2-hour and (d) 48-hour time points. (e) Aspartate levels of leukemia cells 716 
at the 2-hour (FC = fold-change) and (f) 48-hour time points. (g) Change in expression of a 19-717 
gene (PD) score for leukemia cells at the 48-hour time point. (h) Average number of pHistone 718 
H3-positive (+), (i) apoptotic cells measured by cleaved caspase 3, (j) CD34-positive (+), or (k) 719 
MNDA-positive (+) cells per field in the spleen of mice treated with vehicle or IACS-010759 at 720 
the 48–hour time point. c-g, each symbol represents the mean value for 3 technical replicates 721 
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from a single mouse..  h-k, each symbol is the mean of 5 random fields from a single mouse. 722 
Mean ± SEM is provided. *p-value = 0.02, ***<0001, n.s. = not significant by two-sided student 723 
t-test. 724 
  725 
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METHODS 726 
Cell culture.  727 
Unless otherwise specified, all cell lines (H460, 293T, H292, RCC4, RCC4+VHL, Gli56, D423 728 
and NB-1) were cultured in DMEM (Gibco)+ 10%FBS (Sigma). AML cell lines (KG1, THP1, 729 
MOLM13, K562, MV4-11, OCI-AML3, U937, Kasumi, and HL60) were cultured in RPMI 730 
(Gibco) + 5%-20% FBS. D423 cells were provided by D. Bigner (Duncan et al, Oncotarget 731 
2010). Gli56 cells were provided by D.N. Louis (Mueller et al, Oncogene 2005).  NB-1 cells 732 
were obtained from JCRB Cell Bank. All GSCs were kindly provided by Dr. Fred Lang at 733 
MDACC. GSCs were cultured in serum-free DMEM/F12 (ATCC) supplemented with 20 ng/ml 734 
bFGF (Sigma) , 20 ng/ml EGF (Sigma) and 1x B27 supplement (Invitrogen). Normal diploid 735 
cells were purchased from ATCC and cultured following ATCC’s guidelines.  All other cell lines 736 
are from ATCC.  RCC4 and RCC4VHL were obtained from ECACC. Cell lines are maintained 737 
by an internal core facility that routinely uses STR fingerprinting to verify cell line identity and 738 
mycoplasma testing to confirm they are negative.  739 
Compound Synthesis 740 
Step 1: Synthesis of ethyl 3-(4(trifluoromethoxy)phenyl)-1,2,4-oxadiazole-5-carboxylate 741 
To a solution of (E)-N’-hydroxy-4-(trifluoromethoxy)benzimidamide (Sigma-Aldrich, 60.0 g, 742 
272 mmol) and pyridine (32.3 g, 408 mmol) in CHCl3 (400 mL) at 0 oC was slowly added ethyl 743 
2-chloro-2-oxoacetate (44.6 g, 327 mmol). The mixture was stirred at reflux for 3 hrs, cooled to 744 
RT and diluted with H2O (400 mL). The mixture was extracted with DCM (400 mL x2), the 745 
combined organic layers were washed with aq. HCl (1M, 300 mL x 2 ) and H2O (400 mL), dried 746 
over Na2SO4, filtered, evaporated to give ethyl 3-(4(trifluoromethoxy)phenyl)-1,2,4-oxadiazole-747 
5-carboxylate as a light yellow solid (77.7 g, 94%), which was used for next step without further 748 
purification. 1H NMR (300 MHz, CDCl3) δ 8.22 (d, J= 11.2 Hz, 2 H), 7.36 (d, J= 11.2 Hz, 2 H), 749 
4.60 (q, J= 9.6 Hz, 2 H), 1.51 (t, J= 9.6 Hz, 3 H); 13C NMR (126 MHz, DMSO-d6) δ 167.5, 750 
167.1, 153.5, 150.7, 129.5, 124.4, 121.7, 119.9 (q, J = 257 Hz), 63.3, 13.7; 19F NMR (471 MHz, 751 
DMSO-d6) δ -56.7; HRMS (ESI+) m/z: [M+H]+ calcd. for C12H10F3N2O4 303.0587; found 752 
303.0584. 753 
 754 
Step 2: Synthesis of 3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole -5-carbohydrazide 755 
To a solution of ethyl 3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole-5-carboxylate (80.0 g, 756 
265 mmol) in EtOH (800 mL) was added NH2NH2.H2O (85%, 76.0 mL, 1325 mmol). The 757 
reaction mixture was stirred at RT overnight. The desired compound precipitated from the 758 
reaction mixture, was filtered and washed with EtOH (200 mL) to afford 3-(4-759 
(trifluoromethoxy)phenyl)-1,2,4-oxadiazole-5-carbohydrazide (70.2 g, 92%) as a light yellow 760 
solid, which was used for next step without further purification. 1H NMR (600 MHz, Methanol-761 
d4) δ 8.24 (d, J = 8.8 Hz, 2H), 7.47 (d, J = 8.6 Hz, 2H); 13C NMR (126 MHz, DMSO-d6) δ 166.9, 762 
129.4, 124.7, 121.7, 119.9 (q, J = 258 Hz); 19F NMR (471 MHz, DMSO-d6) δ -56.6; HRMS 763 
(ESI+) m/z: [M+H]+ calcd. for C10H8F3N4O3 289.0543; found 289.0538. 764 
 765 
Step3: Synthesis of 5-(5-methyl-1H-1,2,4-triazol-3-yl)-3-(4-(trifluoromethoxy)phenyl)-1,2,4-766 
oxadiazole 767 
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To a mixture of 3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole-5-carbohydrazide (45.0 g, 156 768 
mmol) and acetimidamide hydrochloride (22.2 g, 234 mmol) in THF (500 mL), was added 769 
NaOH (9.4 g, 234 mmol). The mixture was refluxed for 3 days and then cooled to RT, 770 
concentrated under reduced pressure and diluted with H2O (500 mL). The resulting suspension 771 
was stirred at RT for 30 min, and then filtered to afford crude solid product, which was treated 772 
with EtOAc (400 mL). The resulting suspension was stirred at RT for 30 min, and then filtered to 773 
afford 5-(5-methyl-1H-1,2,4-triazol-3-yl)-3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole as a 774 
white solid (30.3 g, 62%). 1H NMR (600 MHz, DMSO-d6) δ 14.65 (s, 1H), 8.22 (d, J = 8.7 Hz, 775 
2H), 7.61 (d, J = 8.6 Hz, 2H), 2.51 (s, 3H); 13C NMR (126 MHz, DMSO-d6) δ 169.4, 167.2, 776 
165.8, 155.3, 150.5, 129.4, 125.0, 121.7, 119.9 (q, J = 258 Hz), 11.5; 19F NMR (471 MHz, 777 
DMSO-d6) δ -56.6; HRMS (ESI+) m/z: [M+H]+  calcd. for C12H9F3N5O2 312.0703; found 778 
312.0699. 779 
 780 
Step 4: Synthesis of 5-(1-(3-bromobenzyl)-5-methyl-1H-1,2,4-triazol-3-yl)-3-(4-781 
(trifluoromethoxy)phenyl)-1,2,4-oxadiazole 782 
To a suspension of 5-(5-methyl-1H-1,2,4-triazol-3-yl)-3-(4-(trifluoromethoxy)phenyl) -1,2,4-783 
oxadiazole (60.0 g, 192.8 mmol) and potassium carbonate (66.6 g, 482.0 mmol) in DMF (200 784 
mL) was added 1-bromo-3-(bromomethyl)benzene (48.2 g, 192.8 mmol). The mixture was 785 
stirred at RT for 16h, then diluted with water (500 mL) and extracted with EtOAc (3 x 500 mL). 786 
The combined organic layers were washed with H2O (300 mL) and concentrated under reduced 787 
pressure to afford the crude product, which was purified by silica gel chromatography column 788 
(eluent: 4:1 to 3:2 PE/EtOAc) to afford 5-(1-(3-bromobenzyl)-5-methyl-1H-1,2,4-triazol-3-yl)-3-789 
(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol as a white solid (53.6 g, 57.9%). 1H NMR (600 790 
MHz, CDCl3) δ 8.28 (d, J = 8.8 Hz, 2H), 7.48 (d, J = 7.9 Hz, 1H), 7.41 (s, 1H), 7.34 (d, J = 8.8 791 
Hz, 2H), 7.26 (d, J = 7.6 Hz, 1H), 7.17 (d, J = 7.9 Hz, 1H), 5.43 (s, 2H), 2.55 (s, 3H);  13C NMR 792 
(126 MHz, DMSO-d6) δ 168.9, 167.2, 155.4, 150.5, 148.2, 137.8, 131.0, 131.0, 130.5, 129.4, 793 
126.9, 124.9, 121.9, 121.6, 119.9 (q, J = 258 Hz),  51.1, 11.6; 19F NMR (471 MHz, DMSO-d6) δ 794 
-56.6; HRMS (ESI+) m/z: [M+H]+ calcd. for C19H14BrF3N5O2 480.0277, 482.0257;  found 795 
480.0270, 480.0247. 796 
 797 
Step 5: Synthesis of IACS-010759 5-(5-methyl-1-(3-(4-(methylsulfonyl)piperidin-1-yl)benzyl)-798 
1H-1,2,4-triazol-3-yl)-3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole 799 
To a mixture of 5-(1-(3-bromobenzyl)-5-methyl-1H-1,2,4-triazol-3-yl)-3-(4-  800 
(trifluoromethoxy)phenyl)-1,2,4-oxadiazole (2.00 g, 4.16 mmol), 4-(methylsulfonyl)piperidine 801 
(1.02 mg, 6.24 mmol), and t-BuONa (800  mg, 8.33 mmol) in toluene (80 mL), 2-802 
dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl (580 mg, 1.25 mmol) and 803 
tris(dibenzylideneacetone)dipalladium (760 mg, 0.83 mmol) were added and the reaction mixture 804 
was  degassed with argon for 3 mins, then heated to 140 ℃ for 18 hrs under argon 805 
atmosphere.  The mixture was then cooled to RT, diluted with EtOAc (100 mL), filtered through 806 
a pad of celite, washed with EtOAc (100 mL) and concentrated under reduced pressure.  The 807 
residue was purified by silica gel chromatography column (PE: EtOAc = 1:1 to pure EtOAc) to 808 
crude product, which was treated with EtOAc and Et2O (v: v = 1:9, 30 mL). The resulting 809 
suspension was stirred at RT for 30 min, and then filtered to afford 5-(5-methyl-1-(3-(4-810 
(methylsulfonyl)piperidin-1-yl)benzyl)-1H-1,2,4-triazol-3-yl)-3-(4-(trifluoromethoxy)phenyl)-811 
1,2,4-oxadiazole as a white solid (905 mg, 39%). 1H NMR (600 MHz, DMSO-d6) δ 8.22 (d, J = 812 
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8.8 Hz, 2H), 7.61 (d, J = 8.2 Hz, 2H), 7.21 (t, J = 7.9 Hz, 1H), 6.97 (bs, 1H), 6.94 (dd, J = 8.3, 813 
2.4 Hz, 1H), 6.64 (d, J = 7.5 Hz, 1H), 5.48 (s, 2H), 3.86 (bd, J = 13.4 Hz, 2H), 3.28 (m, 1H), 814 
2.94 (s, 3H), 2.76 (m, 2H), 2.57 (s, 3H), 2.06 (bd, J = 13.4 Hz, 2H), 1.68 (ddd, J = 16.5, 12.5, 4.1 815 
Hz, 2H); 13C NMR (126 MHz, DMSO-d6) δ 169.0, 167.2, 155.1, 150.7, 150.5, 147.9, 136.0, 816 
129.6, 129.4, 124.9, 121.7, 119.9 (q, J = 258 Hz), 117.8, 115.5, 115.2, 58.6, 52.3, 47.2, 37.4, 817 
23.7, 11.7; 19F NMR (471 MHz, DMSO-d6) δ -56.6; HRMS (ESI+) m/z: [M+H]+ calcd. for 818 
C25H26F3N6O4S 563.1683; found 563.1675. 819 
Oxygen consumption  820 
AML cells were suspended normal growth medium at a concentration of 1 x 107 cells/ml and 100 821 
µl of cells were added to Seahorse 96-well plates pre-coated with Cell Tak. Plates were 822 
centrifuged and medium was replaced with pre-warmed (37o C) 125 µl Seahorse medium 823 
(Seahorse XF medium with 2 mM glutamax, 10 mM glucose, 2 mM pyruvate) containing IACS-824 
010759 or rotenone (41 nM). For AML cell lines, 3 x 105 total cells were seeded per well in 825 
Seahorse XF medium with 2 mM glutamine, 10 mM glucose, and 2 mM pyruvate. The 826 
mitostress test was performed with 1 oligomycin µM, 0.4-1 FCCP µM, and 1 antimycin µM. For 827 
oxygen consumption in permeabilized tumor cells (Fig. 1D), H460 cells were suspended in 828 
Seahorse XF assay medium and plated at a concentration of 15 x 103 cells/well of Seahorse 96-829 
well plates pre-coated with Cell Tak. Plates were centrifuged and medium was replaced with pre-830 
warmed (37º C) 100 µl of 10 mM pyruvate/ 2mM malate substrate + 4 µM FCCP (uncoupled) in 831 
the 1x Mitochondria Assay Solution (MAS) media. Immediately prior to IACS-010759 injection, 832 
Plasma Membrane Permeabilizer (PMP) was added to 1 nM and ADP was added to a final 833 
concentration of 4 nM. Final drug/substrate concentrations were: IACS-010759 10, 100 or 1000 834 
nM; rotenone 100 nM; succinate 10 mM antimycin 4 µM. A detailed protocol is provided by 835 
Seahorse   http://www.seahorsebio.com/resources/tech-writing/XF_PMP_Protocol.pdf.  836 
Seahorse analyses for AML cell lines and the PDX model was performed according to Seahorse 837 
Biosciences protocol for the mitostress test. Briefly, 300,000 cells per well were seeded in 175 838 
uL of Seahorse XF medium supplemented with 10 mM glucose, 2 mM glutamine, and 1 mM 839 
pyruvate. FCCP concentration was optimized for each cell line model (1.6-0.2 μM) and data was 840 
normalized to cell number.  841 
Seahorse analyses for basal OCAR and ECAR were performed using reagents from Seahorse 842 
Bioscience as previously reported48.   843 
Ectopic expression of NDI-1  844 
HEK293T cells were transfected with  pCMV-dR8.9 packaging DNA vector, pMD2.G VSV-G-845 
expressing envelope vector, and either pLenti6.3 NDI-1, pLenti6.3/V5 NDI-1, or pLenti6.3/V5 846 
GFP plasmid DNA. 2 x 105 H460 cells were transduced in a 6-well plate with 2 ml of viral 847 
supernatant supplemented with polybrene to a final concentration of 8 µg/ml.  After infection, 848 
transduced cells were selected by growing in 7 µg/ml blastacidin.  The concentration of IACS-849 
010759 used in the graph in Fig. 1e was 14 nM. 850 
Isolated mouse complex I assay.  851 
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Complex I was isolated from mouse heart mitochondria using an adaptation of the method of 852 
Sharpley and coworkers 49.  The concentration of IACS-010759 in Fig. 1f was 60 nM. The 853 
NADH:decylubiquinone assay is described in Sharpley et al. 49 and the APAD+ and H2O2 assays 854 
are described in Birrell et al. 50. 855 
Generation of clonal cell lines resistant to IACS-010759  856 
H292 cells (1x106 cells/plate) were seeded in 15 cm dishes in galactose growth medium and 857 
treated with 1 nM IACS-010759 (IC65) 1 nM IACS-010759 for 3 weeks, followed by exposure to 858 
8 nM IACS-010759 (IC95) until resistant clones emerged. Twenty-six resistant clones were 859 
isolated from 4 independent experiments were seeded at 5x103 cells/well in 96-well plates in 100 860 
µl galactose growth medium. After cells became fully attached, IACS-010759 or rotenone was 861 
added to final concentrations of 370 nM-18 pM for 3 days. Plates were scanned in in IncuCyte® 862 
live-cell analysis system prior to analysis via Hoechst and PI. Subsequently, both Hoechst and PI 863 
using an Operetta high-content imaging system.RNAseq was conducted on the parental line and 864 
12 resistant clones, uncovering a single non-synonymous, heteroplasmic (35% to 50%), recurrent 865 
mutation in the mitochondrial-encoded gene MT-ND1 in 9 of the 12 resistant clones that 866 
conferred the following amino-acid change: L>55F (T>3469C). Paired-end reads were initially 867 
aligned to transcript sequences of complex I genes with Bowtie 2 51 and the aligned fragments 868 
were probabilistically assigned to transcripts using eXpress 52. Variants from the reference 869 
genome were called using the mpileup command in SAMtools. MutPred 53 analysis of the L>55F 870 
variant classifies the alteration as potentially pathogenic (MutPred score = 0.8); this alteration is 871 
found at a very low frequency in mtDNA sequences in Genebank (1:30589 based on full-length 872 
mitochondrial genomes deposited in Genebank prior to October 28th, 2015), suggesting it is 873 
unlikely to be a polymorphism. The mutation was confirmed in four of the resistant clones by 874 
cloning the MT-ND1 gene sequence (ZERO blunt PCR [Invitrogen]) and analyzing purified 875 
plasmid DNA via Sanger sequencing using the following primers: Forward: 876 
GTAAAACGACGGCCAGT and Reverse: AACAGCTATGACCATG.  877 
Metabolomics for glycolysis deficient models 878 
NB-1, D423, Gli56, A1207, SW1088 and U87 were plated and treated with DMSO or 100 nM 879 
IACS-010759 in 10-cm plate with adjusted density in the goal to reach similar density at the time 880 
of harvesting.  Two days after, the cells were briefly washed in cold PBS, scrapped in 80% 881 
methanol, and spun down.  The supernatant was dried in a GeneVac HT4 using the low 882 
temperature program (SP Scientific).  The dried samples were resuspended and subjected to LC-883 
MS analysis that covers over 200 metabolites at Dr John M Asara’s group at Beth Israel 884 
Deaconess Medical Center, as previously described 54.  Analysis of metabolite peak area 885 
integrated total ion chromatogram values was carried out in R. Metabolites with missing data in 886 
any sample were excluded, and the remaining values were quantile normalized. Statistical 887 
comparisons of groups was performed with limma, and all p-values reported were corrected for 888 
multiple hypothesis testing by the Benjamini and Hochberg method. 889 
LC-MS for targeted metabolomics and stable-isotope tracing in AML cell lines 890 
For targeted metabolomics, dried cellular extracts from OCI-AML3 cultures were reconstituted 891 
with 1:1 acetonitrile:water (40 uL) and aliquots (5 uL) were analyzed on an Agilent 1290 ultra-892 
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high performance liquid chromatography (UHPLC) system coupled with an Agilent 6550 893 
quadrupole-time of flight (Q-TOF) mass spectrometer operating in negative ion mode. Details 894 
about LC-MS analysis conditions are reported in Appendix I. Acquired Q-TOF raw data was 895 
processed using Agilent MassHunter Profinder 8.0 software and target metabolites were 896 
identified using the built-in batch targeted feature extraction algorithm which utilized an in-897 
house accurate mass-retention time (AMRT) database library including 126 endogenous 898 
metabolites. Identified compound signal intensities were extracted and subjected to statistical 899 
analysis in Agilent Mass Profiler Professional (MPP). Sample metabolite raw abundancies were 900 
log2 transformed, normalized by their correspondent sample protein content or viable cell count 901 
and centered to their median signal intensities. The unpaired Welch’s t-test was used to 902 
determine statistically significant variations across sample groups (For detailed methodology 903 
refer to Appendix I). 904 
For stable-isotope tracing experiments, samples for LC-MS analysis were prepared as described 905 
above and analyzed on an Agilent 6550 Q-TOF. The raw data was analyzed in MassHunter 906 
Profinder 8.0 by running the batch isotopologue extraction algorithm against an AMRT in-house 907 
compound library including the compounds of interest. The resulting isotopologue abundancies 908 
were corrected for their isotopic natural abundance, extracted as detailed CVS files, and tested 909 
for significant variations using a Welch’s t-test. Details about cell growth and LC-MS analysis 910 
are reported in Appendix I (For detailed methodology refer to Appendix I).   911 
Primary AML cells and normal bone marrow 912 
Peripheral blood samples from patients with AML were collected during routine diagnostic 913 
procedures after informed consent was obtained in accordance with the regulations and protocols 914 
(LAB 01-473) approved by the MDACC Investigational Review Board (IRB) in accordance with 915 
IRB regulations of The University of Texas MD Anderson Cancer Center and the Declaration of 916 
Helsinki. AML samples were analyzed under the Investigational Review Board-approved 917 
laboratory protocol PA13-1025. Briefly, mononuclear cells were separated by Ficoll-Hypaque 918 
density gradient centrifugation and incubated in RBC lysis buffer (ammonium chloride solution) 919 
to remove red blood cells. Primary leukemia samples were maintained in StemEZ Serum-Free 920 
Medium. Viability and induction of apoptosis were assessed simultaneously using flow 921 
cytometry. 1-3 million cells were grown in triplicate in 24-well plates and exposed to DMSO or 922 
IACS-010759. Cells were harvested after 3, 4 or 5 days of exposure to agent and resuspended in 923 
binding buffer containing Annexin V. Apoptotic cells were detected by Annexin V flow 924 
cytometry after gating on CD45+ leukemic cells. Viable cells were detected by flow cytometry 925 
with anti–human CD45-FITC antibody (BD Pharmingen) staining after exclusion of nonviable 926 
cells by diamidino-2-phenylindole (DAPI; Sigma-Aldrich) and apoptotic cells. Flow Cytometry 927 
was performed on Gallios Flow Cytometer and data analyzed using Kaluza Flow Analysis 928 
software (Beckman Coulter). For normal bone marrow, the same procedure was followed. 929 
Gene expression signature 930 
To determine whether specific gene pathways were altered by treatment with IACS-010759, 931 
REACTOME pathway analysis was performed on the genes that were significantly up-regulated 932 
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(132 genes) or down-regulated (132 genes) in >2 cell lines by 24-hour treatment with 100 nM 933 
IACS-010759. The top four gene pathways upregulated in response to IACS-010759 were all 934 
related to amino acid biosynthesis (Supplementary Fig. 13a), consistent with the findings 935 
described above that metabolite levels are altered in response to IACS-010759. The fifth 936 
pathway up-regulated included genes regulated by ATF4, which is a transcription factor that 937 
upregulates genes that that deal with cellular stress in response to decreased amino acids and 938 
energy intermediates. The top 5 down-regulated pathways all involve genes involved in cell 939 
cycle progression (Supplementary Fig. 13b). 940 
Genes whose expression was modulated by treatment with IACS-010759 in >3 cell lines were 941 
selected for validation in vivo with a custom NanoString codeset. Samples from an acute PK/PD 942 
study conducted in a primary patient-derived AML mouse xenograft model were harvested in 943 
triplicate after 48 hours of treatment with 1, 2.5, and 7.5 mg/kg IACS-010759 and in duplicate 944 
for the vehicle. Analysis of NanoString data was carried out using the statistical computing 945 
language R. Normalization factors were calculated based on the internal positive controls and a 946 
selected set of housekeeping genes (CLTC, TBP, ALAS1, ACTB, and RPL19) according to the 947 
nCounter Expression Data Analysis Guide.  For each sample, to control for variability in 948 
hybridization across samples, the geometric mean of the internal controls is calculated and then 949 
used to normalize across samples.  To control for variability associated with the amount of input 950 
mRNA, the geometric mean of the housekeeping genes is calculated and then used to normalize 951 
samples for the amount of input mRNA.  Data were normalized to vehicle samples, and genes 952 
ranked by the magnitude of alteration at the highest dose (Supplementary Fig. 8c). A subset of 953 
genes were dose-dependently downregulated upon treatment, with > 2 fold decrease in 954 
expression at the highest dose of IACS-010759 (Supplementary Fig. 13c, d,e). Variability in 955 
mRNA signal for each gene was minimal across the three mice within a dosing group.  956 
The top scoring gene was IL8 and it was equally inhibited at all three dose levels (Supplementary 957 
Figs. 13d,e).  In contrast, other genes showed a dose-dependent inhibition over this range 958 
(Supplementary Figs. 13d,e).  A ‘summary score’ was constructed based on the average fold 959 
change of the 12 genes for which the highest dose-dependent downregulation was observed in 960 
response to IACS-010759 (RRM2, HMGN2, DHCR24, PCNA, KIF11, TK1, KLGAP25, KIF20A, 961 
CDCA5, CCNB1 and FEN1) and plotted vs. plasma levels for the PK/PD analysis shown in 962 
Supplementary Fig. 13f.   963 
This analysis shows a dose-dependent decrease in expression of this group of genes in response 964 
to IACS-010759 treatment. 965 
 966 
Life Sciences Reporting Summary 967 
Additional details on experimental details and design are available in the Life Sciences Report Summary. 968 
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